BRAF and colorectal carcinoma: Simultaneous inhibition of Wnt and MAPK signals is currently in clinical testing for the treatment of a subset of BRAF-mutant CRC patients, employing Cetuximab, LGX818 and the Wnt ligand maturation inhibitor WNT974 [138](Fig. 3, Table 1).